Skip to main content
. 2023 Jun 21;10(24):2300881. doi: 10.1002/advs.202300881

Figure 5.

Figure 5

Inhibiting ANO1 augments the effectiveness of anti‐PD‐1 immunotherapy against GI cancers. The effectiveness of anti‐PD‐1 antibody (aP) in A) MC38‐derived xenografts and B) CT26‐derived xenografts after ANO1 knockdown. The effectiveness of anti‐PD‐1 antibody in C) MC38‐derived xenografts and D) CT26‐derived xenografts after treated with ANO1 inhibitors CAI/BBR. E) A flow chart for the establishment of a MC38‐R string with acquired resistance to anti‐PD‐1 antibody. F) Expression of ANO1 in MC38‐R CDX after acquired resistance to anti‐PD‐1 antibody. G) The effectiveness of anti‐PD‐1 antibody in MC38‐R CDXs after treated with CAI. *p < 0.05. ns, not significant. Error bars, mean ± SEM.